Trial Outcomes & Findings for A Novel Device for the Management of ADHD (NCT NCT05777785)
NCT ID: NCT05777785
Last Updated: 2025-03-25
Results Overview
The Adult ADHD Self-Report Scale (ASRS) is a self-report instrument that comprises eighteen items that correspond with the DSM-V-TR criteria for ADHD. Subjects are asked to rate 18 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 72, based on the sum of all 18 questions. Higher scores mean more symptoms and higher ADHD's impairments. Lower values represent better outcomes. The ASRS has two subscales that can be used to identify ADHD subtypes - Inattentiveness and Hyperactivity/Impulsivity. Each subscale contains 9 questions.
COMPLETED
NA
108 participants
Baseline, 2 months
2025-03-25
Participant Flow
108 partcipants met the inclusion criteria. Two participants failed to comply with the personalization process due to difficulty staying awake or using a cell phone during the test, resulting in 106 participants receiving the intervention.
Participant milestones
| Measure |
Active
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Overall Study
STARTED
|
106
|
|
Overall Study
COMPLETED
|
100
|
|
Overall Study
NOT COMPLETED
|
6
|
Reasons for withdrawal
| Measure |
Active
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
5
|
|
Overall Study
Lost to Follow-up
|
1
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Active
n=97 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Age, Continuous
|
26.51 years
STANDARD_DEVIATION 4.59 • n=97 Participants
|
|
Sex: Female, Male
Female
|
51 Participants
n=97 Participants
|
|
Sex: Female, Male
Male
|
46 Participants
n=97 Participants
|
|
Adult ADHD Self-Report Scale (ASRS) - Total Score
|
39.76 units on a scale
STANDARD_DEVIATION 12.10 • n=97 Participants
|
|
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale
|
21.2 units on a scale
STANDARD_DEVIATION 6.68 • n=97 Participants
|
|
Adult ADHD Self-Report Scale (ASRS) - Hyperactivity/Impulsivity subscale
|
18.56 units on a scale
STANDARD_DEVIATION 6.64 • n=97 Participants
|
PRIMARY outcome
Timeframe: Baseline, 2 monthsPopulation: Two participants did not complete the questionnaire.
The Adult ADHD Self-Report Scale (ASRS) is a self-report instrument that comprises eighteen items that correspond with the DSM-V-TR criteria for ADHD. Subjects are asked to rate 18 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 72, based on the sum of all 18 questions. Higher scores mean more symptoms and higher ADHD's impairments. Lower values represent better outcomes. The ASRS has two subscales that can be used to identify ADHD subtypes - Inattentiveness and Hyperactivity/Impulsivity. Each subscale contains 9 questions.
Outcome measures
| Measure |
Active
n=95 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
Baseline
|
39.76 score on a scale
Standard Error 1.24
|
|
Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
End of study
|
38.27 score on a scale
Standard Error 1.31
|
PRIMARY outcome
Timeframe: Baseline, 2 monthsPopulation: Two participants did not complete the questionnaire.
The inattentiveness sub-scale of the ASRS measures difficulties with focusing on details, organisation, remembering appointments, making careless mistakes, and concentration. It includes 9 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 36, based on the sum of all questions. Higher scores mean more symptoms and higher inattentiveness' impairments.
Outcome measures
| Measure |
Active
n=95 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up
Baseline
|
21.20 score on a scale
Standard Error 0.69
|
|
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up
End of study
|
20.22 score on a scale
Standard Error 0.72
|
SECONDARY outcome
Timeframe: 2 monthsPopulation: Nine participants did not participate in the clinicial interview.
Based on an interview with the participant, the clinician rates the total improvement on a 7 point scale as follows: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.
Outcome measures
| Measure |
Active
n=88 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up
CGI-I score of "1", "2" or "3"
|
77 Participants
|
|
Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up
CGI-I score of "4" or higher
|
11 Participants
|
SECONDARY outcome
Timeframe: Baseline, 2 monthsPopulation: Four participants did not complete the CPT.
Conners' Continuous Performance Test-3 (CPT-3) is an objective test of attention and impulsivity that has been validated in individuals aged 8 years and older. d-prime (d') is a measure of how well the respondent discriminates nontargets (i.e., the letter X) from targets (i.e., all other letters). This variable is also a signal detection statistic that measures the difference between the signal (targets) and noise (non-targets) distributions. In general, the greater the difference between the signal and noise distributions, the better the ability to distinguish non-targets and targets. CPT scores are age and gender standardized T-scores, in which the mean is equal to 50 and the standard deviation is equal to 10. d' is reverse-scored so that higher raw score and T-score values indicate worse performance (i.e., poorer discrimination). Atypical scores are higher than 60 indicating "elevated" to "very elevated" performance.
Outcome measures
| Measure |
Active
n=93 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
Baseline
|
50.03 T-score
Standard Error 0.90
|
|
Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
End of Study
|
47.95 T-score
Standard Error 1.06
|
SECONDARY outcome
Timeframe: Baseline, 2 monthsPopulation: Four participants did not complete the questionnaire.
The Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) is a standardized measure that captures views of adults' executive functions or self-regulation in their everyday environment. Items are rated on a 3-points Likert scale of 1 ('Never') to 3 ('Often'). The Metacognition Index (MI) of the BRIEF-A reflects the individual's ability to initiate activity and generate problem-solving ideas, to sustain working memory, to plan and organize problem-solving approaches, to monitor success and failure in problem solving, and to organize one's materials and environment. The MI subscale includes 40-items with score ranges between 40 to 120. Higher values represent worse outcome and greater difficulties with executive functions.
Outcome measures
| Measure |
Active
n=93 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up
Baseline
|
79.85 score on a scale (raw scores)
Standard Error 1.75
|
|
Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up
End of Study
|
77.76 score on a scale (raw scores)
Standard Error 1.75
|
Adverse Events
Active
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Active
n=100 participants at risk
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
|
|---|---|
|
General disorders
Headache
|
36.0%
36/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Eyestrain
|
20.0%
20/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Dizziness
|
18.0%
18/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Tiredness
|
9.0%
9/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Discomfort
|
7.0%
7/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place